FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

The FDA issued a not approvable letter for NovoCure's Optune Mya device for treating lung cancer brain metastases, citing uncertainty around clinical benefit despite no safety concerns. The rejection compounds investor concerns following lackluster Q3 earnings and competition from Revolution Medicines' newly approved Rasonque pill for pancreatic cancer. NovoCure's stock fell 7.34% on the news, and the analyst recommends against investing in the beaten-down equity.

11/10/2026, 1:50 PM • The Motley Fool

Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?

Revolution Medicines' stock has surged over 150% this year following FDA approval of Rasonque, its pancreatic cancer drug that nearly doubled survival rates. The company's RAS-inhibitor platform has de-risked the biological mechanism with multiple phase 3 trials underway. However, the company remains unprofitable with Q3 losses of $407.5 million despite $198 million in revenue from five weeks of Rasonque sales. Analyst price targets suggest significant upside potential.

11/08/2026, 11:15 AM • The Motley Fool

Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug

Revolution Medicines' pancreatic cancer drug daraxonrasib received FDA approval and could generate peak revenues of $11 billion. Royalty Pharma, which financed the drug, stands to earn up to $340 million in peak royalties without doing the development work. While Revolution Medicines stock has surged 200% in the past year, Royalty Pharma offers a more diversified alternative with investments in 35 approved drugs and a 1.4% dividend yield.

11/08/2026, 10:15 AM • The Motley Fool

Should You Buy Royalty Pharma Stock Before Nov. 4?

Royalty Pharma shares have rallied toward 52-week highs ahead of Q3 2026 earnings on Nov. 4, but investors should focus on long-term prospects rather than short-term earnings catalysts. Analysts expect 8.7% sales growth and flat earnings, with potential upside from positive pipeline updates on cancer treatments and other drug candidates, though negative news on pelacarsen could weigh on the stock.

10/29/2026, 9:30 AM • The Motley Fool

Could Revolution Medicines Be a Millionaire-Maker Stock?

Revolution Medicines (RVMD) has surged over 9x in three years following FDA approval of its cancer drug Rasonque for pancreatic cancer treatment. While the stock has delivered impressive returns, analysts suggest it's unlikely to reach the $1.6 trillion market cap needed to turn a $25,000 investment into $1 million. However, with additional pipeline candidates and analyst support, the company could still generate market-beating returns for long-term investors.

10/29/2026, 4:44 AM • The Motley Fool

Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?

Revolution Medicines received FDA approval for Rasonque, an innovative pancreatic cancer treatment that beat chemotherapy in clinical trials. Billionaire Stanley Druckenmiller's Duquesne Family Office increased its stake by 26.5% in Q2. While the stock has surged 134% and currently trades at a $40B market cap, the analyst suggests waiting for a $5B market cap reduction before buying, citing the need for a better margin of safety in the volatile biotech sector.

10/27/2026, 5:41 PM • The Motley Fool

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight

The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.

10/26/2026, 1:00 PM • GlobeNewswire

These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead

Revolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history.

10/15/2026, 3:14 PM • The Motley Fool

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.

09/02/2026, 5:50 PM • GlobeNewswire

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.

08/28/2026, 7:07 AM • The Motley Fool

Onco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib)

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Revolution Medicines for the launch of RASONQUE (daraxonrasib), a RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma. The drug showed significant clinical benefits in the phase 3 RASolute-302 trial, with median PFS of 7.3 months and OS of 13.2 months in RAS G12 mutation patients compared to 3.5 months and 6.6 months respectively for chemotherapy.

08/26/2026, 6:17 PM • GlobeNewswire

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

The FDA has approved RASONQUE (daraxonrasib), developed by Revolution Medicines, as the first targeted RAS inhibitor for treating metastatic pancreatic adenocarcinoma in patients who have received prior systemic therapy or are not candidates for multiagent chemotherapy. In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% compared to chemotherapy, with median overall survival of 13.2 months versus 6.7 months, and demonstrated manageable safety with improved quality of life measures.

08/26/2026, 12:59 PM • GlobeNewswire

ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS

A securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 must act by August 10, 2026 to serve as lead plaintiff.

08/08/2026, 4:51 PM • GlobeNewswire

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights

A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price declined approximately 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.

08/07/2026, 3:47 PM • GlobeNewswire

ERAS 3-DAY DEADLINE ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens Berman

Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials, triggering a $2.8 billion market capitalization loss. Investors with substantial losses can serve as lead plaintiffs with an August 10, 2026 deadline.

08/07/2026, 3:44 PM • GlobeNewswire